Arcus Biosciences, a clinical-stage biopharmaceutical company headquartered in Hayward, California is advancing the development of innovative cancer therapies. The company is currently focused on several pipeline products, including Domvanalimab, an anti-TIGIT investigational monoclonal antibody in Phase 2 and Phase 3 clinical trials, AB308 - another anti-TIGIT monoclonal antibody in Phase 1b clinical trials, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist in Phase 2 clinical trials, Quemliclustat - a small-molecule CD73 inhibitor in Phase 1b and Phase 2 clinical trials, Zimberelimab - an anti-PD-1 antibody in Phase 2 clinical trials for metastatic cell lung cancer and monotherapy, and AB521, an oral and small-molecule inhibitor of HIF-2a in Phase 1 clinical trials for the treatment of Von Hippel-Lindau disease. The company also has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial for patients with unresectable Stage 3 NSCLC. Additionally, BVF Partners L.P. is supporting the company's discovery and development of compounds for the treatment of inflammatory diseases.
Arcus Biosciences's ticker is RCUS
The company's shares trade on the NYSE stock exchange
They are based in Hayward, California
There are 201-500 employees working at Arcus Biosciences
It is arcusbio.com
Arcus Biosciences is in the Healthcare sector
Arcus Biosciences is in the Biotechnology industry
The following five companies are Arcus Biosciences's industry peers: